$NIKI
Niki BioSolutions, Inc.
CIK:0001734005|SEC Filings
Consolidated Statements of Cash Flows - USD ($) |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2025 |
Dec. 31, 2024 |
Dec. 31, 2023 |
|
| Cash flows from operating activities | |||
| Net loss | $ (1,376,430) | $ (4,157,737) | $ (4,340,975) |
| Adjustments to reconcile net loss to net cash used in operating activities | |||
| Amortization and depreciation | 255,046 | 1,125,254 | |
| Issuance cost in relation to warrant | 153,189 | ||
| Change in fair value of warrant liability | (690,000) | ||
| Share-based compensation | 1,265,189 | ||
| Loss on investments in marketable securities, net | 9,266 | ||
| Unrealized loss (gain) from fair value change of the long-term investments, net | (6,431,088) | ||
| Impairment loss of long-term investment | 1,000,000 | 77,200 | |
| (Gain) loss on disposal of long-lived assets | (58,621) | 110,852 | |
| Impairment loss on long-lived assets | 1,699,481 | 750,381 | |
| Allowance for credit loss of due from a related party | 521,007 | ||
| Write-off of prepayment and other receivables | 45,677 | 62,369 | |
| Write-off of accounts receivable | 6,280 | ||
| Write-down of inventories | 13,206 | ||
| Gain on disposal of subsidiaries | (703) | ||
| Amortization of right-of-use assets | 50,520 | 252,345 | |
| Interest expense and accretion of convertible debts | 180,000 | 180,000 | 45,266 |
| Reversal of deferred cash bonus | (1,646,228) | ||
| Changes in operating assets and liabilities | |||
| Accounts receivable | 41,349 | 126,717 | |
| Inventories | 14,516 | ||
| Other receivables and prepayments | 17,506 | 291,078 | 227,457 |
| Long-term deposits | 29,106 | ||
| Amounts due from related parties | 961 | 63,050 | |
| Amounts due to related parties | (464) | 464 | (8,524) |
| Accounts payable and accrued expenses | (28,368) | (422,705) | 398,635 |
| Operating lease liabilities | (91,979) | (120,824) | (389,365) |
| Net cash used in operating activities | (1,836,546) | (1,189,734) | (7,724,364) |
| Cash flows from investing activities | |||
| Purchases of property and equipment | (3,015) | ||
| Proceeds from disposal of property and equipment | 58,621 | 15,385 | |
| Proceeds from sales of investment securities | 93,215 | ||
| Loan to a related party | (92,459) | ||
| Repayment of loan and interest from a related party | 611,641 | ||
| Net cash provided by investing activities | 58,621 | 624,767 | |
| Cash flows from financing activities | |||
| Loan from related parties | 2,500,000 | ||
| Proceeds from issuance of Class A Ordinary Shares and warrant | 2,000,000 | 1,575,562 | |
| Exercise of share options | 16,506 | ||
| Payments related to offering costs | (284,001) | ||
| Repayment of bank loan | (3,000,000) | ||
| Proceeds from issuance of convertible notes | 3,000,000 | ||
| Proceeds from issuance of Class A Ordinary Shares | 3,070,000 | ||
| Payments related to offering costs | (370,800) | ||
| Net cash provided by financing activities | 4,415,199 | 4,092,068 | |
| Net increase (decrease) in cash and cash equivalents and restricted cash | 2,578,653 | (1,131,113) | (3,007,529) |
| Cash and cash equivalents – Beginning of year | 874,238 | 2,005,351 | 5,012,880 |
| Cash and cash equivalents – End of year | 3,452,891 | 874,238 | 2,005,351 |
| Supplemental disclosures of cash flow information | |||
| Interest paid | 94,108 | ||
| Non-cash operating, investing and financing activities | |||
| Reclassification of placement agent warrant redemption amount | 47,000 | ||
| Right-of-use assets obtained in exchange for new operating lease liabilities | 338,525 | ||
| Convertible notes converted to Class A Ordinary Shares | 6,000,000 | ||
| Settlement of deferred cash bonus by issuance of share options | $ 451,660 | $ 3,078,196 | |
Consolidated Balance Sheets - USD ($) |
Dec. 31, 2025 |
Dec. 31, 2024 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 3,452,891 | $ 874,238 |
| Other receivables and prepayments | 139,633 | 85,316 |
| Total current assets | 3,592,524 | 959,554 |
| Long-term investments, net | 15,098,846 | 15,098,846 |
| Long-term deposits | 71,823 | |
| Total Assets | 18,691,370 | 16,130,223 |
| Current liabilities: | ||
| Accounts payable and accrued expenses | 1,071,715 | 918,611 |
| Operating lease liabilities, current | 24,428 | 102,225 |
| Total current liabilities | 4,593,823 | 4,338,980 |
| Operating lease liabilities, non-current | 14,182 | |
| Warrant liability | 306,000 | |
| Total Liabilities | 4,899,823 | 4,353,162 |
| Commitments and contingencies (Note 21) | ||
| TEMPORARY EQUITY | ||
| Contingently redeemable warrants | 47,000 | |
| Total temporary equity | 47,000 | |
| EQUITY | ||
| Additional paid-in capital | 97,000,188 | 93,474,825 |
| Accumulated other comprehensive (loss) income | (92,310) | 89,162 |
| Accumulated deficit | (73,792,798) | (72,429,528) |
| Total equity attributable to the shareholders of Aptorum Group Limited | 23,115,160 | 21,134,514 |
| Non-controlling interests | (9,370,613) | (9,357,453) |
| Total equity | 13,744,547 | 11,777,061 |
| Total Liabilities, Temporary Equity and Equity | 18,691,370 | 16,130,223 |
| Class A Ordinary Shares | ||
| EQUITY | ||
| Ordinary shares, value | 62 | 37 |
| Class B Ordinary Shares | ||
| EQUITY | ||
| Ordinary shares, value | 18 | 18 |
| Related Party | ||
| Current liabilities: | ||
| Amounts due to related parties | 79,180 | 79,644 |
| Convertible notes to a related party | $ 3,418,500 | $ 3,238,500 |